Equity Research, Broker Reports, and media content on ELI LILLY & CO

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about ELI LILLY & CO
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on ELI LILLY & CO. We currently have 0 research reports from 0 professional analysts.

Date Source Announcement
05Dec16 01:00 PRN U.S. FDA approves Jardiance® (empagliflozin) tablets to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease
02Dec16 03:30 PRN Lilly Confirms Date and Conference Call for 2017 Financial Guidance Announcement
30Nov16 07:34 PRN Lilly Introduces Scholars Programs for Florida A&M University's and Howard University's Business Students
23Nov16 11:45 PRN Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial
22Nov16 02:00 PRN Survey Reveals Most People Don't Know Heart Disease Is the No. 1 Killer of People with Type 2 Diabetes
14Nov16 02:00 PRN Baricitinib Demonstrates Early Response Compared to Placebo and Significant Improvement Compared to Adalimumab in Patient-Reported Outcomes
14Nov16 02:00 PRN New Analyses of Phase 3 Trials Show Improvements in Rheumatoid Arthritis Symptoms Following Treatment with Baricitinib Across Diverse Population of Patients
  • Frequency of research reports

     

  • Research reports on

    ELI LILLY & CO

  • Providers covering

    ELI LILLY & CO